BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference

JUPITER, Fla., May 21, 2013 /PRNewswire/ -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announced that Mark Weinreb, its President and CEO, will be presenting at the Marcum MicroCap Conference.  

The conference will be held on Thursday, May 30, 2013 at the Grand Hyatt Hotel, located at 109 E 42nd Street in New York City.  Mr. Weinreb's presentation will take place at 2:30 ET in room six.  To listen to the webcast, please visit http://wsw.com/webcast/marcum/brtx.

The event will host nearly 100 publicly traded companies with capitalizations under $500 million. It is anticipated that the conference will be attended by more than 1,000 persons, including senior personnel from the presenting public companies, leading institutional investors, directors, bankers and service providers to the microcap marketplace. The conference will also feature panels on subjects highly relevant to small-cap corporate finance.

For full event details and registration information, please go to:
www.marcumllp.com/microcap

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ("BRT"), www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:

• brtxDISC™ Program (Disc Implanted Stem Cells), a non-surgical treatment for bulging and herniated discs that addresses the gap between non-invasive and invasive back procedures.  This research is still in the non-clinical, investigational stage.
• ThermoStem® Program, a treatment for metabolic disorders (diabetes, heart disease, etc.) and obesity using brown fat stem cells. Initial non-clinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
• brtx-C Cosmetic Program, based on the development of a human cellular extract that, per initial in vitro studies, when applied to human skin cells, appears to cause an increase in the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin.  Potential cosmetic uses are being explored with third parties.

The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at www.stempearls.com.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contact:
Jeff Ramson

ProActive Capital
(646) 863-6341

[email protected]

SOURCE BioRestorative Therapies, Inc.